Header

UZH-Logo

Maintenance Infos

Immunological challenges for peptide-based immunotherapy in glioblastoma


Mohme, Malte; Neidert, Marian C; Regli, Luca; Weller, Michael; Martin, Roland (2014). Immunological challenges for peptide-based immunotherapy in glioblastoma. Cancer Treatment Reviews, 40:248-258.

Abstract

Glioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment modalities are therefore needed, and these should be able to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological approaches in principle meet these needs. Unfortunately, due to profound tumor-associated mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide vaccination have so far not been translated into clinical success. If future, peptide-based vaccination approaches shall be successful in glioblastoma therapy, multiple questions need to be solved including identification of suitable antigens, route and mode of vaccination, preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past.

Abstract

Glioblastoma is the most aggressive primary tumor of the central nervous system with a medium overall survival of 7-15months after diagnosis. Since tumor cells penetrate the surrounding brain tissue, complete surgical resection is impossible and tumor recurrence is almost a certainty. New treatment modalities are therefore needed, and these should be able to trace, identify, and kill dispersed tumor cells with great accuracy. Immunological approaches in principle meet these needs. Unfortunately, due to profound tumor-associated mechanisms of immunosuppression and -evasion, immunotherapeutic strategies like peptide vaccination have so far not been translated into clinical success. If future, peptide-based vaccination approaches shall be successful in glioblastoma therapy, multiple questions need to be solved including identification of suitable antigens, route and mode of vaccination, preparation of the tumor-bearing "host" and antagonizing, as much as this is possible, glioblastoma-associated mechanisms of immune evasion and poor vaccination response. In this review we will address the immunological challenges of glioblastoma and discuss key aspects that have rendered successful immunotherapy difficult in the past.

Statistics

Citations

16 citations in Web of Science®
17 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

231 downloads since deposited on 25 Nov 2013
55 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurosurgery
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2014
Deposited On:25 Nov 2013 08:31
Last Modified:05 Apr 2016 17:11
Publisher:Elsevier
ISSN:0305-7372
Additional Information:The final publication is available at Springer via http://dx.doi.org/10.1016/j.ctrv.2013.08.008
Publisher DOI:https://doi.org/10.1016/j.ctrv.2013.08.008
PubMed ID:24064197

Download

Download PDF  'Immunological challenges for peptide-based immunotherapy in glioblastoma'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 1MB
View at publisher